Page last updated: 2024-11-12

k 134 compound

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

OPC 33509: has both anti-thrombotic and anti-hyperplastic activities; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9908900
CHEMBL ID284838
SCHEMBL ID5383733
MeSH IDM0508586

Synonyms (24)

Synonym
CHEMBL284838
k-134
opc-33509
k134 ,
189362-06-9
k134 compound
k 134 compound
6-(3-(3-cyclopropyl-3-(2-hydroxycyclohexyl)ureido)propoxy)-2(1h)-quinolinone
k-134 compound
urea, n-cyclopropyl-n'-(3-((1,2-dihydro-2-oxo-6-quinolinyl)oxy)propyl)-n-((1r,2r)-2-hydroxycyclohexyl)-
opc 33509
j9j6nk6w4u ,
unii-j9j6nk6w4u
SCHEMBL5383733
DTXSID90172346
AKOS027337121
(-)-6-(3-(3-cyclopropyl-3-((1r,2r)-2-hydroxycyclohexyl)ureido)-propoxy)-2(1h)-quinolinone
HY-U00186
CS-7279
DB12685
1-cyclopropyl-1-((1r,2r)-2-hydroxycyclohexyl)-3-(3-((2-oxo-1,2-dihydroquinolin-6-yl)oxy)propyl)urea
Q27281383
MS-26772
1-cyclopropyl-1-[(1r,2r)-2-hydroxycyclohexyl]-3-[3-[(2-oxo-1h-quinolin-6-yl)oxy]propyl]urea

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Safety evaluations performed during 14- and 28-day visits which included in-clinic dosing and assessments at peak drug concentrations provided core data for the DMC review."( Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
Brass, EP; Connor, JT; Cooper, LT; Hiatt, WR; Lewis, RJ; Murphy, JR; Teerlink, JR, 2011
)
0.37
" On the other hand, the effects of cilostazol on MCA occlusion time and cerebral infarct size are relatively weak even at the high dosage of 300 mg/kg."( K-134, a phosphodiesterase 3 inhibitor, prevents brain damage by inhibiting thrombus formation in a rat cerebral infarction model.
Asanuma, A; Ashikawa, Y; Hidaka, H; Inoue, Y; Itoh, S; Nakagawa, T; Tanabe, S; Yoshida, H, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID184172In vivo anti-hyperplastic activity was evaluated by the inhibition of balloon injury model in rats at a dose of 30 mg/kg (p.o.)1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
AID167829In vitro inhibitory activity against Adenosine diphosphate (ADP) induced rabbit platelet aggregation1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
AID134685In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 30 mg/kg (p.o.)1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
AID167830In vitro inhibitory activity against collagen induced rabbit platelet aggregation1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
AID134684In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 10 mg/kg (p.o.)1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
AID184049In vivo anti-hyperplastic activity was evaluated by the inhibition of balloon injury model in rats at a dose of 10 mg/kg (p.o.)1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (8.33)18.2507
2000's3 (25.00)29.6817
2010's6 (50.00)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.32 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]